tbuckley/cabot-search huggingface dataset:
Targeting α-synuclein by PD03 AFFITOPE® and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance
Authors: Miguel Lemos, Serena Venezia, Violetta Refolo, Antonio Heras-Garvin, Sabine Schmidhuber, Armin Giese, Andrei Leonov, Sergey Ryazanov, Christian Griesinger, Gergana Galabova, Guenther Staffler, Gregor Karl Wenning, Nadia Stefanova
Journal: Translational Neurodegeneration (2020)

Abstract Background Misfolded oligomeric α-synuclein plays a pivotal role in the pathogenesis of α-synucleinopathies including Parkinson’s disease and multiple system atrophy, and its detection parallels activation of microglia and a loss of neurons in the substantia nigra pars compacta. Here we aimed to analyze the therapeutic efficacy of PD03, a new AFFITOPE® immunotherapy approach, either alone or in combination with Anle138b, in a PLP-α-syn mouse model. Methods The PLP-α-syn mice were treated with PD03 immunotherapy, Anle138b, or a combination of two. Five months after study initiation, the mice underwent behavioral testing and were sacrificed for neuropathological analysis. The treatment groups were compared to the vehicle group with regard to motor performance, nigral neuronal loss, microglial activation and α-synuclein pathology. Results The PLP-α-syn mice receiving the PD03 or Anle138b single therapy showed improvement of gait deficits and preservation of nigral dopaminergic neurons associated with the reduced α-synuclein oligomer levels and decreased microglial activation. The combined therapy with Anle138b and PD03 resulted in lower IgG binding in the brain as compared to the single immunotherapy with PD03. Conclusions PD03 and Anle138b can selectively target oligomeric α-synuclein, resulting in attenuation of neurodegeneration in the PLP-α-syn mice. Both approaches are potential therapies that should be developed further for disease modification in α-synucleinopathies.
1563P Early clinical trials in patients with pancreatic cancer: Assessment of factors limiting eligibility and effectiveness
Authors: F. Kerbage, M.P. Ducreux, R. Eid, V. Boige, D. Malka, M. Gelli, A. Perret, C. Smolenschi, C. Prieux, L. Verlingue, P. Martin-Romano, C. Massard, A. Hollebecque
Journal: Annals of Oncology (2020)
1745P SARS-CoV-2 infects metabolically-primed epithelial cells in lung cancer models
Authors: K.R. Cargill, C.A. Stewart, C. Gay, K. Ramkumar, R. Cardnell, M. Nilsson, S. Heeke, E.M. Park, L. Diao, Q. Wang, L. Shen, X. Le, Y. Xi, K. Kundu, D. Gibbons, J. Wang, J.V. Heymach, L.A. Byers
Journal: Annals of Oncology (2020)
INCREASED FORMATION OF SPLANCHNIC VASCULAR ANGIOTENSIN-(1-7) FROM ANGIOTENSIN I AND ANGIOTENSIN II IS MEDIATED BY ANGIOTENSIN CONVERTING ENZYME-2 IN EXPERIMENTAL CIRRHOSIS AND PORTAL HYPERTENSION
Authors: Josephine A Grace, Chandana B Herath, Zhiyuan Jia, Louise M Burrell, Peter W Angus
Journal: Hepatology (2011)
Conditioned-Reflex Treatment of Alcoholism
Authors: Joseph Thimann
Journal: New England Journal of Medicine (1949)

IN THE first article about the conditioned-reflex therapy its rationale and technic were discussed.1 The purpose of the present study is to show the risks, indications, contraindications, efficacy and psychotherapeutic aspects.To establish a reflex association between alcoholic beverages and vomiting, emetine hydrochloride is used as the unconditioned stimulus. The pharmacologic interest in emetine started with its use for treatment of amebic dysentery, liver abscesses and alveolar pyorrhea.Emetine is one of the alkaloids of ipecacuanha. Its pharmacologic properties were the object of extensive studies during the greater part of the nineteenth century. However, not until 1893 did Paul and . . .
FGFR1 Is Critical for RBL2 Loss–Driven Tumor Development and Requires PLCG1 Activation for Continued Growth of Small Cell Lung Cancer
Authors: Kee-Beom Kim, Youngchul Kim, Christopher J. Rivard, Dong-Wook Kim, Kwon-Sik Park
Journal: Cancer Research (2020)

Small cell lung cancer (SCLC) remains a recalcitrant disease where limited therapeutic options have not improved overall survival, and approved targeted therapies are lacking. Amplification of the tyrosine kinase receptor FGFR1 (fibroblast growth factor receptor 1) is one of the few actionable alterations found in the SCLC genome. However, efforts to develop targeted therapies for FGFR1-amplified SCLC are hindered by critical gaps in knowledge around the molecular origins and mediators of FGFR1-driven signaling as well as the physiologic impact of targeting FGFR1. Here we show that increased FGFR1 promotes tumorigenic progression in precancerous neuroendocrine cells and is required for SCLC development in vivo. Notably, Fgfr1 knockout suppressed tumor development in a mouse model lacking the retinoblastoma-like protein 2 (Rbl2) tumor suppressor gene but did not affect a model with wild-type Rbl2. In support of a functional interaction between these two genes, loss of RBL2 induced FGFR1 expression and restoration of RBL2 repressed it, suggesting a novel role for RBL2 as a regulator of FGFR1 in SCLC. Additionally, FGFR1 activated phospholipase C gamma 1 (PLCG1), whereas chemical inhibition of PLCG1 suppressed SCLC growth, implicating PLCG1 as an effector of FGFR1 signaling in SCLC. Collectively, this study uncovers mechanisms underlying FGFR1-driven SCLC that involve RBL2 upstream and PLCG1 downstream, thus providing potential biomarkers for anti-FGFR1 therapy. SIGNIFICANCE: This study identifies RBL2 and PLCG1 as critical components of amplified FGFR1 signaling in SCLC, thus representing potential targets for biomarker analysis and therapeutic development in this disease.
681P Clinical and immune responses to immunotherapy in biochemically recurrent (non-metastatic castration sensitive) prostate cancer (BCRpc)
Authors: R.A. Madan, S. Slovin, L.C. Harshman, X.X. Wei, M. Bilusic, F.H. Karzai, R.N. Donahue, N.J. Toney, J. Strauss, L. Cordes, P. Arlen, M. Rauckhorst, S. Wroblewski, A. Couvillon, A. Hankin, N. Williams, W. Dahut, J. Schlom, P.W. Kantoff, J.L. Gulley
Journal: Annals of Oncology (2020)
1602P Estimated years of potential life lost from lack of access to crizotinib: NSCLC ALK+
Authors: B.D. Cruz, G. Lenz, R.A. Pellegrini, L.S. Lago, P.S. Azevedo, L.L. Tôrres, G. Lopes, J.A. Teodoro
Journal: Annals of Oncology (2020)
1216P A circulating exosomal miRNA-based risk score as a predictive biomarker of relapse in early stage non-small cell lung cancer
Authors: G. Rossi, S. Coco, L. Longo, G. Chiorino, P. Ostano, M.G. Dal Bello, M. Grassi, C. Venturi, L. Mastracci, M. Tagliamento, C. Dellepiane, L. Zullo, K. Beshiri, A. Alama, E. Bennicelli, A. Bottini, P. Pronzato, C. Genova
Journal: Annals of Oncology (2020)
840P Famitinib malate plus camrelizumab for recurrent platinum-resistant ovarian/fallopian tube/primary peritoneal cancer and advanced cervical cancer: An open-label, multicenter phase II study
Authors: L. Xia, Q. Zhou, Y. Zhang, Y. Gao, W. Hu, M. Pan, G. Lou, L. Wang, H. Shi, J. Zhu, H. Sun, X. Wang, Q. Wang, X. Wu
Journal: Annals of Oncology (2020)
1705P SARS-CoV-2 infection among cancer patients receiving antitumor treatment in Italy: A nationwide observational study (CIPOMO ONCO COVID-19)
Authors: M.E. Negru, C. Tondini, A. Pastorino, M. Caccese, A. Cariello, A. Bertolini, G. Buzzatti, S. Cinieri, A. Comandone, F. Grossi, M. Franchini, O. Caffo, O. Garrone, A. Mambrini, F. Leone, C. Chini, F. Agustoni, F. Artioli, L. Blasi, C. Aschele
Journal: Annals of Oncology (2020)
LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial
Authors: P. Nathan, R. Dummer, G.V. Long, P.A. Ascierto, H.A. Tawbi, C. Robert, P. Rutkowski, O. Leonov, C. Dutriaux, M. Mandala', P. Lorigan, P.F. Ferrucci, K.T. Flaherty, J.C. Brase, S. Green, T. Haas, A. Masood, E. Gasal, A. Ribas, D. Schadendorf
Journal: Annals of Oncology (2020)
470P Anti-tumor mechanisms of rigosertib in colorectal cancer
Authors: S.M. Hassanian Mehr, F. Rahmani, M. Hashemzehi, A. Avan, F. Barneh, F. Asgharzadeh, R. Moradi-Marjaneh, A. Soleimani, M. Parizadeh, G.A. Ferns, M. Ghayour Mobarhan, M. Ryzhikov, A.R. Afshari, M.R. Ahmadian, E. Giovannetti, M. Jafari, A.R. Rezaei, M. Khazaei
Journal: Annals of Oncology (2020)
Figures of the <scp>H</scp>eart <scp>F</scp>ailure <scp>A</scp>ssociation: <scp>P</scp>rof. <scp>L</scp>ars <scp>H. L</scp>und, <scp>C</scp>hair of the <scp>HFA C</scp>ommittee on <scp>R</scp>egistries, <scp>S</scp>urveys and <scp>E</scp>pidemiology and <scp>HFA B</scp>oard <scp>M</scp>ember (from 2016)
Authors: Andrew J.S. Coats
Journal: European Journal of Heart Failure (2020)
872P Comparison of colposcopy, pap smear test and visual inspection with acetic acid (VIA) as screening tests for precancer of the cervix (CIN2+) in high risk patients
Authors: Z. Zawua, J.E. Omietimi, I. Jeremiah, S. Aigere, S. Musa, N. Osegi, P.W. Oweisi
Journal: Annals of Oncology (2020)
936P Outcome and toxicity in older patients with locoregionally-advanced head and neck cancer: Relevance of an oncogeriatric approach
Authors: S. Llop, M. Taberna Sanz, M. Plana, M. Oliva, J. Brenes, M. Honorato, V. Gomez, J. Nogués, R. Mesía, A. Lozano, M. Antonio
Journal: Annals of Oncology (2020)
1945P Distribution of anti-PD1/PDL1 autoantibodies in multiple cancer types and potential biomarker role for anti-PD1 therapy
Authors: Q. Tan, Y. Wang, S. Liu, R. Luo, S. Wang, T. Liang, J. Yang, P. Xing, J. Yao, D. Wu, Z. Zhang, J. Dai, X. Yu, X. Han, Y. Shi
Journal: Annals of Oncology (2020)
1749P COVID-19 impact and predictive factors for mortality in cancer patients
Authors: E. Sanz Garcia, P. Peinado, I. Moreno, M. Dorta, B. Alvarez, R. Alvarez Gallego, R. Madurga, J. Rodriguez Pascual, L. Ugidos, C. Muñoz, E. Garcia-Rico, A. Cubillo
Journal: Annals of Oncology (2020)
Letter by Gill Regarding Article, “White Blood Cells and Blood Pressure: A Mendelian Randomization Study”
Authors: Dipender Gill
Journal: Circulation (2020)

The recent article by Siedlinski and colleagues 1 in Circulation investigated the relationship between circulating white blood cell counts and systemic blood pressure measures.Using conventional observational and mendelian randomization approaches, the authors concluded that an elevated lymphocyte count may play a causal role in the development of hypertension. 1 The work was carefully performed and offers useful advances.Given recent developments in mendelian randomization methods, additional analyses could be performed to offer further insight.First, in their conventional observational analysis, the authors identified evidence of nonlinear trends in the association between lymphocyte count and blood pressure traits.For example, there was a greater difference in blood pressure between the fifth and fourth quintiles of lymphocyte count than between the second and first quintiles.In contrast, the mendelian randomization analysis that was performed assumed that there was a linear effect of lymphocyte count on blood pressure.Methods for investigating nonlinear mendelian randomization effects of genetically predicted lymphocyte count on blood pressure are available 2 and could be incorporated.Second, the authors noted that white blood cell indexes correlate with each other.Their mendelian randomization results identified effects of genetically predicted eosinophil count on diastolic blood pressure.Because the genetic variants used as instruments for lymphocyte count are likely to affect eosinophil count also, it is unclear whether the observed association of genetically predicted lymphocyte count on blood pressure would persist after adjustment for genetically predicted eosinophil count.Multivariable mendelian randomization methods to disentangle this are available 3 and could be incorporated.Third, the authors concluded that the molecular mechanisms underlying the association between genetically predicted lymphocyte count and blood pressure might involve pathways related to albuminuria.This was based on an association between genetically predicted lymphocyte count and the ratio of urinary albumin to creatinine.Formal mendelian randomization mediation analysis methods to investigate whether any effect of genetically predicted lymphocyte count on blood pressure traits might be occurring through albuminuria are available 4 and could be incorporated.To summarize, mendelian randomization methods continue to grow and offer opportunity to draw additional insight into strengthening the conclusions of genetic analyses.When feasible and appropriate, they might be incorporated to this effect.
Functional analysis and cryo-electron microscopy of <i>Campylobacter</i> <i>jejuni</i> serine protease HtrA
Authors: Urszula Zarzecka, Alessandro Grinzato, Eaazhisai Kandiah, Dominik Cysewski, Paola Berto, Joanna Skorko-Glonek, Giuseppe Zanotti, Steffen Backert
Journal: Gut Microbes (2020)

Campylobacter jejuni is a predominant zoonotic pathogen causing gastroenteritis and other diseases in humans. An important bacterial virulence factor is the secreted serine protease HtrA (HtrACj), which targets tight and adherens junctional proteins in the gut epithelium. Here we have investigated the function and structure of HtrACj using biochemical assays and cryo-electron microscopy. Mass spectrometry analysis identified differences and similarities in the cleavage site specificity for HtrACj by comparison to the HtrA counterparts from Helicobacter pylori and Escherichia coli. We defined the architecture of HtrACj at 5.8 Å resolution as a dodecamer, built of four trimers. The contacts between the trimers are quite loose, a fact that explains the flexibility and mobility of the dodecameric assembly. This flexibility has also been studied through molecular dynamics simulation, which revealed opening of the dodecamer to expose the proteolytically active site of the protease. Moreover, we examined the rearrangements at the level of oligomerization in the presence or absence of substrate using size exclusion chromatography, which revealed hexamers, dodecamers and larger oligomeric forms, as well as remarkable stability of higher oligomeric forms (> 12-mers) compared to previously tested homologs from other bacteria. Extremely dynamic decay of the higher oligomeric forms into lower forms was observed after full cleavage of the substrate by the proteolytically active variant of HtrACj. Together, this is the first report on the in-depth functional and structural analysis of HtrACj, which may allow the construction of therapeutically relevant HtrACj inhibitors in the near future.
1724P Changes in the outpatient and inpatient clinic admissions during COVID-19 pandemic: Anticipating and mitigating risks for cancer patients
Authors: D.C. Guven, B.Y. Aktas, M.S. Aksun, E. Ucgul, T.K. Sahin, H.C. Yildirim, G. Guner, N. Kertmen, O. Dizdar, S. Kilickap, S. Aksoy, Ş. Yalçın, A. Turker, F.M. Uckun, Z. Arik
Journal: Annals of Oncology (2020)
816MO AGO DESKTOP III/ENGOT OV20: Impact of surgical characteristics and time to first subsequent therapy (TFST)
Authors: F. Lecuru, A. du Bois, J. Sehouli, I.B. Vergote, G. Ferron, A. Reuss, W. Meier, S. Greggi, P. Jensen, F. Selle, F. Guyon, C. Pomel, R. Zang, E.H. Avall-Lundqvist, J-W. Kim, J. Ponce, F. Raspagliesi, G-M. Sadaf, A. Reinthaller, P. Harter
Journal: Annals of Oncology (2020)
539P Patient-reported outcomes (PROs) from patients (Pts) with NTRK fusion-positive (NTRK-fp) solid tumours receiving entrectinib in the global phase II STARTRK-2 study
Authors: A.P. Conley, G.D. Demetri, R.C. Doebele, A. Drilon, L. Paz-Ares, P. Cassier, S. Siena, M-J. Ahn, G.L. Buchschacher, T. Seto, C.E. Chee, M. Krzakowski, S-H.I. Ou, C. Grohé, V. Zagonel, A. Spira, A. Cheng, A. Kapre, E. Piault, C.D. Rolfo
Journal: Annals of Oncology (2020)
738P Soluble PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTN2A1 as predictive biomarkers of nivolumab response in patients with metastatic clear cell renal carcinoma
Authors: L. Incorvaia, D. Fanale, G. Badalamenti, J.L. Iovanna, C. Porta, M. Rizzo, L. Corsini, C. Brando, M. Bono, M. La Mantia, D. Olive, V. Gristina, N. Gri, A. Fiorino, V. Bazan, A. Russo
Journal: Annals of Oncology (2020)
1778P Clinical research at the time of COVID-19: A passion or a real job?
Authors: C. Cagnazzo, S. Testoni, R. Cenna, A. Guarrera, M. Monti, S. Stabile, I. Federici, C. Taverniti, S. Pirondi, A. Ferrari, F. Fragioli
Journal: Annals of Oncology (2020)
Racism, Not Race, Drives Inequity Across the COVID-19 Continuum
Authors: Rohan Khazanchi, Charlesnika T. Evans, Jasmine R. Marcelin
Journal: JAMA Network Open (2020)

Rafi Kabarriti, MD; N. Patrik Brodin, PhD; Maxim I. Maron, MSc; Chandan Guha, MD, PhD; Shalom Kalnicki, MD; Madhur K. Garg, MD, MBA; Andrew D. Racine, MD, PhD
461P Real-time PCR-based assessment of RAS/BRAF mutations in the plasma of metastatic colorectal cancer (mCRC) patients: A single institution experience
Authors: P.P. Vitiello, V. De Falco, E.F. Giunta, D. Ciardiello, M.A. Canciello, C. Cardone, P. Vitale, N. Zanaletti, C. Borrelli, L. Poliero, M. Terminiello, G. Arrichiello, V. Caputo, G. Martini, S. Napolitano, A. Lombardi, M. Caraglia, T. Troiani, F. Ciardiello, E. Martinelli
Journal: Annals of Oncology (2020)
1123P A phase Ib study of rose bengal disodium and anti-PD-1 in metastatic cutaneous melanoma: Initial results in patients refractory to checkpoint blockade
Authors: J.S. Zager, A.S. Sarnaik, S. Pilon-Thomas, M. Beatty, D. Han, G. Lu, S.S. Agarwala, M. Ross, K. Shirai, R. Essner, B. Smithers, V. Victoria Atkinson, E. Wachter
Journal: Annals of Oncology (2020)
Therapeutic targeting of KSP in preclinical models of high-risk neuroblastoma
Authors: Karin Hansson, Katarzyna Radke, Kristina Aaltonen, Jani Saarela, Adriana Mañas, Jonas Sjölund, Emma M. Smith, Kristian Pietras, Sven Påhlman, Krister Wennerberg, David Gisselsson, Daniel Bexell
Journal: Science Translational Medicine (2020)

KSP inhibition results in cell death through mitotic arrest and causes regression of neuroblastoma PDX tumors in mice.
979TiP POPPY: A phase II trial to assess the efficacy and safety profile of pembrolizumab in patients with performance status 2 with recurrent or metastatic squamous cell carcinoma of the head and neck
Authors: S. Forsyth, K. Yip, B. Foran, P. Gougis, G. Wheeler, L. White, A. Chandrakumar, K. Blair, Y. Pathak, V. Spanswick, H. Lowe, J. Hartley, M. Forster
Journal: Annals of Oncology (2020)
Unraveling the Obesity Paradox Through Bariatric Surgery
Authors: Kaifeng Liang, Zheyuan Chen
Journal: JAMA Surgery (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data
Authors: Claire L Vale, David Fisher, Andrew Kneebone, Christopher Parker, Maria Pearse, Pierre Richaud, Paul Sargos, Matthew R Sydes, Christopher Brawley, Meryem Brihoum, Chris Brown, Sylvie Chabaud, Adrian Cook, Silvia Forcat, Carol Fraser-Browne, Igor Latorzeff, Mahesh K B Parmar, Jayne F Tierney
Journal: The Lancet (2020)
1953P Gender and molecular aspects of targeted therapy recommendations for therapy refractory solid tumours: Data from the real-world precision medicine platform MONDTI
Authors: H. Taghizadeh, M. Unseld, R. Mader, L. Müllauer, T. Füreder, M. Spalt, M. Raderer, M. Sibilia, M.A. Hoda, S. Aust, S. Polterauer, W. Lamm, R. Bartsch, M. Preusser, G. Prager
Journal: Annals of Oncology (2020)
1474P Immune-inflammatory indexes and BMI as predictors of outcome and treatment response in advanced gastric cancer receiving ramucirumab-containing second-line
Authors: M. Rimini, M. Salati, A. Bocconi, B. Riccò, G. Rovesti, F. Caputo, C. Santini, C. Bardasi, M.L. Riggi, F. Canino, A. Casadei Gardini, F. Gelsomino, S. Benatti, M. Dominici, G. Luppi, A. Spallanzani
Journal: Annals of Oncology (2020)
CN41 The use of the Edmonton Symptom Assessment scale in advanced lung cancer patients
Authors: M. Lavdaniti, K. Patrikou, I. Tsatsou, M. Tsiligiri, P.M. Prapa, K. Loulouda, C. Loulouda, A. Chatzinikolaou, D. Palitzika, E. Zioga, E. Drakou, K. Marmara, G. Tzavelas
Journal: Annals of Oncology (2020)
Trends in Diagnosis of HIV Infection, Linkage to Medical Care, and Viral Suppression Among Men Who Have Sex with Men, by Race/Ethnicity and Age — 33 Jurisdictions, United States, 2014–2018
Authors: William L. Jeffries, André F. Dailey, Chan Jin, Jarvis W. Carter, Lamont Scales
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

During 2018, gay, bisexual, and other men who have sex with men (MSM) accounted for 69.4% of all diagnoses of human immunodeficiency virus (HIV) infection in the United States (1). Moreover, in all 42 jurisdictions with complete laboratory reporting of CD4 and viral load results,* percentages of MSM linked to care within 1 month (80.8%) and virally suppressed (viral load <200 copies of HIV RNA/mL or interpreted as undetected) within 6 months (68.3%) of diagnosis were below target during 2018 (2). African American/Black (Black), Hispanic/Latino (Hispanic), and younger MSM disproportionately experience HIV diagnosis, not being linked to care, and not being virally suppressed. To characterize trends in these outcomes, CDC analyzed National HIV Surveillance System
1741P Triage procedures for COVID-19 in an Italian cancer centre
Authors: G. Targato, D. Zara, R. Fioraso, L. Bortot, G. Pelizzari, C. Corvaja, L. Palmero, F. Puglisi, C. Andreetta, G.G. Cardellino, A.M. Minisini, G. Fasola
Journal: Annals of Oncology (2020)
Rapid upfront stalk transection for endoscopic resection of pedunculated colorectal lesions using a grasping-type scissor forceps
Authors: Vincent Zimmer
Journal: Endoscopy (2020)

The basic paradigm in endoscopic resection of pedunculated colorectal lesions includes hot snare polypectomy (HSP) with mechanical bleeding prevention techniques [1]. However, when larger, floppy polyps are present and/or the lesions are located in angulations, full endoscopic control of resection may not be guaranteed. Some groups have explored endoscopic submucosal dissection (ESD) for this purpose, and this is potentially of special relevance in cases of short- and wide-stalked lesions [2] [3]. By contrast, a more simplified and less time-consuming approach, relying on scissor-type knives, has been reported as an endoscopic bailout after conventional technique failure [4].
216P The impact of pregnancy-associated breast cancer (PABC) according to immunohistochemical (IHC) subtype: A matched case-control study
Authors: W. Muñoz-Montaño, C. De la Garza-Ramos, A. Tabares, P. Cabrera-Galeana, V. Perez, F. Porras Reyes, D. Sanchez Benitez, A. Olvera, A. Alvarado-Miranda, F. Lara-Medina, A. Mohar Betancourt, E. Bargallo-Rocha, R. Vazquez-Romo, O. Arrieta, C. Villarreal-Garza
Journal: Annals of Oncology (2020)
LBA37 A blinded, randomized, parallel group, comparative investigation of a novel device (Cooral) for cryoprevention of oral mucositis
Authors: J. Walladbegi, A. Svanberg, M. Jontell, R.K. Henriksson, F. Schjesvold, G. Larfors, B. Tavelin, M. Jädersten
Journal: Annals of Oncology (2020)